DUOnco™ Unity, the First CE-Marked Multi-Organ AI Solution for Cancer Monitoring on CT Scans

- **A world first:** DUOnco™ Unity is the first CE-marked AI solution to combine automated detection, segmentation and longitudinal tracking of focal lesions within a single certified device for chest-abdomen-pelvis (CAP) scan interpretation support.
- **A clear clinical objective:** a solution designed to help transform oncology follow-up by providing more objective and standardized assessment of treatment response.
- **A successful industry-academia partnership within the French healthcare ecosystem**, bringing together Intrasense, Guerbet, Gustave Roussy and Angers University Hospital.
- **Strong public support:** development backed by BPI France.

Montpellier, France, August 21, 2026, at 8:45 a.m. CET. Intrasense (ISIN: FR0011179886 – Ticker: ALINS), a French specialist in medical imaging solutions, announces that its new oncology follow-up solution, DUOnco™ Unity, has obtained CE marking under the European Medical Device Regulation (MDR 2017/745).

With this certification, DUOnco™ Unity becomes the world's first CE-marked multi-organ artificial intelligence solution (MDR 2017/745) designed to assist in the interpretation of oncological CT scans. The solution is the first certified software to combine automated detection, segmentation and longitudinal tracking of focal lesions across CAP scan examinations within a single tool, representing a significant advance that streamlines and enhances CT scan interpretation for radiologists.

The Challenges of Chest-Abdomen-Pelvis CT Interpretation in Oncology

Advances in cancer therapies are transforming cancer into a chronic disease, with patients being monitored over many years. Medical imaging plays a central role throughout this journey. Chest-abdomen-pelvis CT has become the reference examination for oncology follow-up because it covers a large anatomical area in a single acquisition, including organs commonly affected by primary tumors and metastases such as the lungs, liver and pancreas.

However, the challenge is no longer simply reading an image: clinicians must assess disease evolution from one scan to the next, identify new lesions, confirm tumor regression and quantify overall tumor burden. This comparative reading, which is becoming more frequent and repetitive, significantly increases interpretation time. While a CT scan generated around fifty image slices a decade ago, radiologists today routinely review several hundred to more than a thousand slices per examination.

An AI Solution Designed to Transform Oncology Follow-Up

DUOnco™ Unity redefines chest-abdomen-pelvis CTscan analysis through artificial intelligence, built around **four key capabilities**:

- **Automated detection** of focal lesions across multiple organs, including the lungs, liver, bones, lymph nodes, kidneys, pancreas and peritoneum, covering the most common metastatic sites.
- **Automated segmentation** of the vast majority of focal lesions, enabling three-dimensional analysis and a comprehensive view of disease burden.

- **Longitudinal lesion tracking**, facilitating assessment against RECIST 1.1 criteria and supporting a more standardized evaluation of treatment response.
- **Biomarkers:** the solution provides access to quantitative contextual information that has traditionally been difficult to measure manually, including changes in overall lesion burden and patient body composition (muscle mass and adipose tissue).

DUOnco™ Unity turns imaging data into quantitative, precise and reproducible data. By expanding the depth of information extracted from imaging examinations, DUOnco™ Unity supports healthcare professionals in refining their assessment of disease progression throughout the patient care pathway.

"With DUOnco™ Unity, we are reaching a new scale in oncology imaging analysis. We can now assess disease in its entirety by analyzing, in three dimensions, all visible lesions identified on a CT scan. For radiologists, this provides valuable support in making tumor burden assessment more objective and standardized.

This innovation represents a major evolution in clinical practice, enabling us to move from a partial assessment to a comprehensive, quantitative and reproducible view of disease. It is a significant and practical step forward in support of increasingly personalized precision medicine, with one clear objective: improving patient care," said **Prof. Nathalie Lassau**, radiologist within the Imaging Department at Gustave Roussy and an internationally recognized expert in artificial intelligence applied to radiology.

DUOnco™ Unity: A Collaborative Development

DUOnco™ Unity has been developed with the clinical objective of transforming oncology follow-up through AI-assisted analysis and interpretation of oncological CT scans.
By combining the technological expertise and agility of Guerbet and Intrasense with the frontline clinical experience of Gustave Roussy, Europe's leading cancer center, and Angers University Hospital, DUOnco™ Unity has been designed to fit seamlessly into everyday clinical practice.

"This partnership between healthcare industry experts and leading academic clinical centers reflects a shared ambition to redefine the standards of oncology follow-up. The CE marking of DUOnco™ Unity represents a major accelerator for our product strategy, enabling this high-value innovation into routine clinical practice" said **Stephen Armand, Chief Executive Officer of Intrasense.**

DUOnco™ Unity is an initiative supported by BPI France.

Next financial announcement:
2026 Half-Year Results: September 28 (after market close)

About Intrasense

A French expert in medical imaging since 2004 and a digital subsidiary of the Guerbet Group since 2023, Intrasense develops medical imaging software solutions that are now firmly focused on artificial intelligence.
Intrasense's product portfolio includes:

- Myrian® (currently being divested), an advanced visualization platform equipped with state-of-the-art clinical tools that simplifies the interpretation of all types of images.
- DUOnco™: a suite of AI algorithms specialized in oncology, including those for the detection of pancreatic lesions and focal liver lesions, as well as the world's first CE-certified AI dedicated to bone lesions.
  Liflow® (still in the controlled-release phase), a solution designed for the longitudinal monitoring of oncology patients.

By combining clinical expertise and operational excellence, Intrasense provides healthcare professionals with tools of high medical value that facilitate the analysis, diagnosis, and care of patients.
For more information, visit: www.intrasense.fr

Contacts

INTRASENSE
Communication officer
Mathilda Vigne-Salade
Phone: +334 67 13 01 30
investisseurs@intrasense.fr

SEITOSEI.ACTIFIN
Analyst & Investor Relations
Foucauld Charavay
Phone: +336 37 83 33 19
intrasense@seitosei-actifin.com

Press Relations
Isabelle Dray
Phone: +33 6 85 36 85 11
isabelle.dray@seitosei-actifin.com